Exane cuts Fresenius Medical Care, cites US volume concerns
BUZZ-Exane cuts Fresenius Medical Care, cites US volume concerns ** Exane BNP Paribas downgrades Fresenius Medical Care FMEG.DE to "underperform" from "neutral", seeing risks to U.S. dialysis sales volumes
** Broker expects U.S. volumes to fall by 40 bps in Q2, and stay lower for longer likely prompting a cut to the German kidney dialisys provider's flat FY volume target
** "This combined with possible pushbacks for the HighVolumeHDF roll-out outside of FME's own clinic network, could put pressure on operating leverage", it says
** Exane BNP Paribas stays below consensus on Fresenius' Q2 and FY adjusted operating income, flagging Affordable Care Act headwinds and potential Fresenius stake sale pressure
** The brokerage adds that recent share run looks unsupported by earnings
** Out of 23 analysts that cover Fresenius Medical Care AG, seven rate the stock "strong buy" or "buy,"nine rate "hold" andseven rate the stock "strong sell" or "sell" - LSEG data
(Reporting by Basile Day)
Recent news on Fresenius Medical Care AG
See all newsFMC seen down as Fresenius cuts stake to 20%
Germany's Fresenius cuts FMC stake to 20%
Brief: Fresenius Investment In Fresenius Medical Care Reduced From Approximately 25% To Approximately 20% Of Issued Share Capital
Brief: Fresenius Medical Care AG ABB Orders Below Eur 39.00 Per Share, Says Book Runner
Brief: Bookrunner Says Fresenius Medical ABB C. 13.4 Mln Shares, Books Are Closed